Amal Therapeutics

Switzerland
Hasle, Lucerne, Switzerland

Company profile

Amal Therapeutics company profile

Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses its proprietary cell penetrating peptide platform to develop and progress therapeutic vaccines in oncology.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2012-01-01, Year

Headquarters

Country code
CH
Continent
Europe

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
9
Total equity funding
$45.2M
Last funding
Series B / $32.6M / 2018-11-12
Last equity funding
Series B / $32.6M
Investors
9
Lead investors
6
Founders
1
Articles
19
Exited on
2019-07-15

Founders and investors

Founders

Madiha Derouazi

Lead investors

3B Future Health FundBioMedPartnersBoehringer Ingelheim Venture FundFoundation for Innovation and Technology (FIT)Swiss Federal Commission for Innovation and TechnologyVenture Kick

Investors

BioMedPartnersBoehringer Ingelheim Venture FundHTGF (High-Tech Gruenderfonds)Venture KickVI Partners